|
|
|
|
LEADER |
02407nam a2200253 u 4500 |
001 |
EB002001729 |
003 |
EBX01000000000000001164630 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
245 |
0 |
0 |
|a Pharmacoeconomic review report: Naltrexone hydrochloride and bupropion hydrochloride (Contrave)
|h Elektronische Ressource
|b (Bausch Health, Canada iInc.) :indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia)
|
246 |
3 |
1 |
|a Naltrexone hydrochloride and bupropion hydrochloride (Contrave)
|
246 |
3 |
1 |
|a Pharmacoeconomic review report for naltrexone hydrochloride and bupropion hydrochloride (Contrave)
|
250 |
|
|
|a Version: Final
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, July 2020
|
300 |
|
|
|a 1 PDF file (29 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH common drug review
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK565298
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a Naltrexone and bupropion (NB; Contrave) is a fixed-dose combination oral tablet indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are obese (body mass index [BMI]: ≥ 30 mg/kg2); or overweight (BMI: ≥ 27 mg/kg2) with the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia). It is available in one combined strength: 8 mg naltrexone hydrochloride and 90 mg bupropion hydrochloride. The recommended dosage for NB is two tablets twice daily. At the submitted price of $2.21 per tablet, the annual cost is expected to be $3,234. The sponsor's reimbursement request was as per the indication. The sponsor submitted a cost-utility analysis comparing NB taken in conjunction with standard management (SM; defined as a reduced-calorie diet and increased physical activity) to SM alone
|